Clinical Trial: Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Diffuse Large B-Cell Lymphoma
Study Type: INTERVENTIONAL
Official Title: A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL
Brief Summary:
The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that:is relapsed (has returned after last treatment) oris refractory (has not responded to last treatment)DLBCL is a type of non-Hodgkin lymphoma (NHL).NHL is a cancer of the lymphatic system.It develops when the body makes abnormal lymphocytes.These lymphocytes are a type of white blood cell that…
Read more